Overview of Alitretinoin

Quick Facts

Property	Description
Active ingredient	Alitretinoin (9-cis-retinoic acid)
Form	Oral capsules, Topical gel
Pharmacological class	Retinoid (First-generation), Pan Retinoic Acid Agonist
General purpose	Cellular regulation and anti-inflammatory effects
Origin	Endogenous retinoid (Vitamin A derivative)

What Type of Medicine is Alitretinoin? (Definition and Classification)

Alitretinoin is a prescription-only medication classified within the family of retinoids, which are compounds chemically derived from vitamin A. It is defined as a first-generation retinoid, distinguished by its action as a pan retinoic acid agonist. This classification refers to the substance's ability to activate all six known retinoid receptor subtypes within the cell nucleus.

The active ingredient is chemically known as 9-cis-retinoic acid, a substance that occurs naturally within the human body and is thus classified as an endogenous retinoid. The compound is characterized by a broad binding affinity, which allows for control over the expression of genes involved in the cell lifecycle.

Composition, Origin, and Forms of Delivery (Composition and Form)

The drug is supplied as a single active ingredient product, with Alitretinoin as the sole therapeutic component. It is made available in two distinct pharmaceutical preparations to allow for different routes of administration.

These forms include oral capsules for systemic treatment, meaning the medicine is distributed throughout the body, and a topical gel formulated for localized application on the skin surface. A differentiating feature of Alitretinoin is that its oral form is utilized for managing certain severe dermatological conditions, while its topical form is primarily used for localized lesions. This dual-form functionality provides therapeutic versatility.

General Purpose: Cellular Regulation and Modulation (High-Level Purpose)

The general therapeutic purpose of Alitretinoin is rooted in its ability to modulate fundamental cellular processes through its influence on gene expression. Its action provides anti-proliferative effects alongside immunomodulatory and anti-inflammatory effects.

By controlling cell growth modulation and promoting differentiation induction, the medicine helps to address underlying cellular dysfunctions. This regulatory action is intended to curb excessive cell multiplication and mitigate inflammatory responses.

What side effects are possible with Alitretinoin?

Possible Side Effects and Safety Information

The safety profile of Alitretinoin is defined by its classification as a systemic retinoid, leading to both frequent, expected side effects and mandatory, high-level safety restrictions documented in official regulatory labels.

Frequency-Classified Adverse Reactions

Adverse reactions are officially classified based on frequency for the oral capsule. Very Common effects (affecting more than 1 in 10 patients) typically involve systemic changes such as headache, hypertriglyceridemia (increased blood fats), hypercholesterolemia, and Liver enzyme elevations. Dry skin and cheilitis (dry lips) are also very common. Common effects (affecting 1 to 10 in 100 patients) include conjunctivitis, Hypothyroidism (decreased thyroid function), and blood changes such as anemia. Topical application primarily results in local reactions like pain, rash, and pruritus at the application site.

Serious Adverse Reactions and Restrictions

Teratogenicity (severe birth defects) is the most critical safety domain, resulting in the drug being strictly contraindicated during pregnancy and for women of childbearing potential unless a formal Pregnancy Prevention Programme (PPP) is followed. Other serious adverse reactions documented in regulatory sources include Benign Intracranial Hypertension (increased pressure around the brain) and rare reports of neuropsychiatric disorders, including depression and suicidal ideation. The drug is also contraindicated in patients with severe hepatic or renal insufficiency.

Key Safety Limitations

Patients taking Alitretinoin are subject to administration-agnostic safety constraints. This includes a prohibition on blood donation during treatment and for one month following discontinuation due to the teratogenic risk. Additionally, concomitant use with tetracycline antibiotics is contraindicated due to an increased risk of Benign Intracranial Hypertension. Regular monitoring of blood lipids and liver enzymes is required during treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Alitretinoin is associated with manifestations consistent with acute Hypervitaminosis A, which is the general toxic syndrome for retinoids. Treatment is strictly supportive, as there is no specific antidote for overdosage documented in official prescribing information.

Documented Overdose Manifestations

Category	Official Regulatory Statement/Entity
Symptom Clusters	Severe headache, nausea, vomiting, diarrhoea, facial flushing, and hypertriglyceridemia are reported in high-exposure contexts. General retinoid toxicity signs include dry skin/lips and bone pain.
Severe Outcomes	The most serious neurological outcome is Benign Intracranial Hypertension (also known as pseudotumor cerebri), which requires immediate cessation of the drug.

Mandatory Emergency Action

Official regulatory guidance requires immediate medical intervention in cases of known or suspected overdosage. When too many oral capsules are taken, the patient is required to contact a doctor, pharmacist, or nearest hospital immediately. If signs of Benign Intracranial Hypertension—such as persistent headache, blurred vision, or vomiting—are observed, the medicine must be STOPPED immediately and urgent medical care must be sought. For accidental swallowing of the topical gel, regulatory sources mandate that the patient seek emergency medical attention.

Therapeutic Uses of Alitretinoin

What Alitretinoin Treats: Main Uses and Benefits

The therapeutic application of Alitretinoin is commonly used across two specialized clinical domains, applied in clinical settings that involve acute or unstable symptom patterns and conditions that have been difficult to manage with initial supportive measures. Primary indications include managing severe, chronic hand eczema that is unresponsive to potent topical corticosteroids, and localized cutaneous lesions associated with AIDS-related Kaposi's Sarcoma.

Systemic Management of Severe, Chronic Hand Eczema

This medicine is commonly used to help with adults experiencing conditions involving inflammatory or irritative processes, specifically severe, long-standing eczema of the hands (Chronic Hand Eczema) relevant in contexts involving heightened systemic burden where topical management has been insufficient. It helps address symptom clusters related to inflammatory or irritative states, including intense pruritus (itching), painful fissures (cracks), excessive scaling, and chronic redness (erythema).

Localized Symptomatic Management of Specific Cutaneous Lesions

Alitretinoin is also applied in addressing specific symptoms related to localized skin growths associated with AIDS-related Kaposi's Sarcoma. This use is considered relevant for managing the symptomatic manifestation and progression of these particular lesions when conditions do not require broader systemic therapy.

Quick Fact: Relief for Severe Chronic Hand Eczema This medicine is commonly used to help manage symptoms when the condition has been unresponsive to high-potency topical steroid creams, often providing supportive relief and improved day-to-day comfort.

Regulatory References

National Institute for Health and Care Excellence (NICE) Guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Alitretinoin — Official Regulatory Information

Alitretinoin (oral capsules) is a systemic retinoid with highly restrictive official eligibility rules due to its potent teratogenicity (risk of severe birth defects).

Category	Eligibility Status
Populations for Whom Use is Allowed	Adults who do not have any contraindications and, for women, comply with the Pregnancy Prevention Programme.
Populations for Whom Use is Contraindicated	Pregnant women, Breastfeeding women, and Women of childbearing potential who are not enrolled in the Pregnancy Prevention Programme (PPP).

Condition-Specific Contraindications:

Use is absolutely contraindicated in patients with a history of hepatic insufficiency, severe renal insufficiency, uncontrolled hypercholesterolemia, uncontrolled hypertriglyceridemia, uncontrolled hypothyroidism, or hypervitaminosis A. The medicine is also contraindicated in case of hypersensitivity to the drug or other retinoids.

Age-Related Eligibility:

Alitretinoin is not recommended for use in the pediatric population (patients under 18 years of age). For older adults (over 65), data are insufficient to definitively determine differences in response compared to younger adults.

Eligibility-Related Restrictions:

Women of childbearing potential are eligible only if they strictly follow all conditions of the mandatory Pregnancy Prevention Programme (PPP), which includes using highly effective contraception for one month before, throughout the duration of, and for one month after treatment, as well as regular pregnancy testing.

What should I know about interactions with other medicines?

Alitretinoin has documented interaction patterns that regulate its co-administration with other medicines and products, established by official regulatory bodies.

Contraindicated Combinations and Toxicity Risk

Co-treatment with systemic Tetracycline antibiotics is strictly prohibited because the combination carries a formally documented risk of causing benign intracranial hypertension (pseudotumor cerebri). The regulatory label also prohibits co-administration with other systemic retinoids due to the official additive risk of Hypervitaminosis A toxicity. Separately, the oral capsule formulation contains soya oil, making its use formally contraindicated in individuals with a known allergy to peanut or soya.

Pharmacokinetic and Metabolic Interactions

The regulatory label documents Alitretinoin as a CYP3A4 substrate. This metabolic factor results in specific pharmacokinetic interactions with medications that modify this enzyme system. Co-administration with Strong CYP3A4 Inhibitors is officially documented to increase the plasma concentration (exposure) of oral Alitretinoin. Conversely, concurrent use of CYP P450 Inducers may officially lead to a reduction in Alitretinoin plasma levels.

Topical and Population-Based Constraints

Specific timing and usage restrictions apply to the topical gel formulation. The label specifies that Mineral Oil must not be applied to the treated area within a two-hour window (before or after) using the gel. Co-use of other topical products on the treated lesions must also be officially avoided concurrently. Furthermore, systemic Alitretinoin is formally contraindicated in patients with documented hepatic insufficiency or severe renal impairment due to its metabolic clearance profile.

Mechanism of Action

How Alitretinoin Works

Genomic Control via Dual Receptor Activation

The action of Alitretinoin is initiated through its unique role as a pan-agonist for all six Retinoid Acid Receptors ( RARs) and Retinoid X Receptors ( RXRs) within the cell nucleus. This simultaneous, comprehensive binding activates functional RAR- RXR complexes that serve as transcription factors, directly regulating the expression of target genes. This engagement of the nuclear machinery establishes a foundational control over cellular processes.

Regulation of Cellular Proliferation and Differentiation

By modulating the genetic code, the mechanism influences the cell growth cycle, promoting the normalization of epidermal differentiation while simultaneously suppressing excessive cellular proliferation and inducing apoptosis in abnormal cells. This action influences underlying cellular processes and contributes to the modulation of epithelial pathway activity.

Immunomodulation and Anti-inflammatory Effect

The drug’s genomic control extends to key immune cells, resulting in the down-regulation of pro-inflammatory cytokines (like TNF-alpha) and a reduction in the functional capacity of antigen-presenting cells. This genomic control results in the modulation of dysregulated immunological signaling on the tissue, contributing to the down-regulation of chronic tissue inflammation.

Dosage and Administration Information

How to Use Alitretinoin: Administration Guidelines

The usage of Alitretinoin is defined by two separate protocols—oral capsules for systemic conditions and a topical gel for localized lesions. All dosing and administration instructions are to be followed as established for the medication.

Official Routes and Dosing

Application Method	Indication	Standard Adult Dosing
Oral Capsules	Severe Chronic Hand Eczema	Recommended starting dose is 30 mg once daily.
Topical Gel (0.1%)	AIDS-related Kaposi's Sarcoma	Apply a generous coating to lesions, typically starting twice daily.

Key Administration Instructions

Oral Use

Timing with Food: Oral capsules must be taken once daily with a main meal to ensure proper absorption.
Duration: A treatment course typically lasts 12 to 24 weeks, depending on the patient's response, with the possibility of re-treatment for relapse.
Dose Adjustment: The dose may be reduced to 10 mg once daily if a patient experiences unacceptable adverse reactions to the 30 mg dose.
Age Groups: No dose adjustment is required for older adults (over 65 years); use in children (under 18) is not established.

Topical Use

Application Frequency: Application starts at twice daily but may be gradually increased to three or four times daily based on individual tolerance. Increases in frequency should be separated by at least two weeks.
Application Rules: The gel should only be applied to the lesions, avoiding normal skin and mucous membranes. Occlusive dressings must not be used.
Drying Time: The gel must be allowed to dry for 3 to 5 minutes before being covered by clothing.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Alitretinoin

Evidence from Studies on Severe, Chronic Hand Eczema

Research has extensively examined the use of Alitretinoin for adults experiencing conditions characterized by fluctuating or episodic manifestations, specifically severe hand eczema in people whose condition was studied after having previously used strong topical steroid creams. The research primarily consists of large, short-term (up to 24 weeks) Randomized Controlled Trials (RCTs) against a placebo, which was used in research exploring how symptoms change over time.

These studies was studied for outcomes related to physical discomfort, primarily by assessing the proportion of participants whose hands reached a status of "clear" or "almost clear," as defined by a physician using a standard score. Short-term RCTs reported patterns observed in the studies where the "clear/almost clear" status, as defined by the study, was documented in a higher proportion of adults taking the oral capsule compared to those who received the placebo pill. Long-term effects are not fully established.

Types of Outcomes Measured in Hand Eczema Trials

The Physician's Global Assessment (PGA) score was used to explore how symptoms evolved, giving a single score to describe the overall severity. Similarly, researchers applied in studies examining patient-reported experiences tools like the Dermatology Life Quality Index (DLQI), which was evaluated in studies to monitor the relationship between the skin condition and daily activities.

Evidence from Studies on Localized AIDS-Related Kaposi's Sarcoma Lesions

The research base for the topical gel formulation was evaluated in studies involving conditions presenting with cycles of stability and flare-ups related to localized skin growths observed in AIDS-related Kaposi's Sarcoma (KS). Studies monitored response rates and reported that the defined tumor response rate was documented in a higher proportion of localized lesions in the group using the topical gel compared to the non-active vehicle gel.

The oral form was studied for this indication in the past; however, research on the systemic form at higher doses was associated with the reporting of events during the study.

Focus on Topical vs. Systemic Research for Kaposi’s Sarcoma

The research has generally focused on the use of the topical gel formulation for managing the localized skin symptoms, while the oral, or systemic, formulation was evaluated in a limited number of earlier trials. Evidence quality varies across studies between the two formulations.

What is Still Uncertain About Alitretinoin Research

The comparative evidence is lacking for how the oral capsule was evaluated in studies against other systemic medicines sometimes used for severe hand eczema. Follow-up durations were limited in the main controlled trials, meaning the full impact on the long-term management of this chronic, relapsing condition is not yet fully understood. Evidence for certain groups remains limited, as there is limited information from controlled trials on the use of this medicine in children or in patients with certain complex co-occurring health conditions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Alitretinoin (FAQ)

Q: What is the difference in use between the oral capsules and the topical gel form of Alitretinoin?

The use of Alitretinoin depends on its formulation. The oral capsules are indicated for use in adults with severe chronic hand eczema that has not responded to treatment with strong topical corticosteroid creams. The topical gel formulation is indicated for localized skin growths associated with AIDS-related Kaposi’s sarcoma.

Q: Does Alitretinoin cure the underlying condition it is prescribed for, or does it only control symptoms?

Regulatory studies do not use the term 'cure' for Alitretinoin. Instead, clinical trials assess outcomes based on the proportion of participants whose condition achieved a status of 'clear' or 'almost clear.' Official documents note that the full impact on the long-term management of this chronic, relapsing condition is not yet fully established due to limited follow-up durations in the main controlled trials.

Q: Is it true that Alitretinoin can sometimes cause muscle and joint pain?

Official product information indicates that musculoskeletal effects can occur. Specifically, joint pain (arthralgia) and muscle pain (myalgia) have been reported as uncommon side effects of the oral capsules, meaning they affect between 1 and 10 in every 1,000 patients.

Q: Does a history of mental health problems affect eligibility for Alitretinoin treatment?

Official warnings note that oral retinoids have been associated with reports of neuropsychiatric disorders, including depression and mood changes. The prescribing information states that particular care and monitoring should be applied to patients with a history of depression.

Q: Can Alitretinoin interact with or reduce the effectiveness of hormonal birth control (the pill)?

The mandatory Pregnancy Prevention Programme (PPP) requires women of childbearing potential to use at least one highly effective method of contraception. Regulatory documents do not state that Alitretinoin reduces the efficacy of hormonal contraceptives, but high contraceptive reliability is mandatory.

Q: Is the simultaneous use of other topical skin products with Alitretinoin gel allowed?

The regulatory label specifies that the concurrent use of other topical products, especially irritating ones, on the treated lesions must generally be avoided. For specific substances, the label also states that products containing mineral oil should not be applied to the treated area within a two-hour window of using the gel.

Q: How long does it typically take to first notice an improvement in the condition while on Alitretinoin?

Official clinical trials assessed the proportion of participants achieving clear or almost clear skin at the end of the treatment course, which typically lasts 12 to 24 weeks. Studies reported that the time required to achieve a response varied based on the intensity of the treatment.

Q: Can Alitretinoin cause changes in the eyes that make it uncomfortable to wear contact lenses?

Alitretinoin can cause side effects that affect the eyes. Common reported effects of the oral capsules include conjunctivitis (inflammation of the outer layer of the eye). Dryness of the eyes is also a possible effect that may lead to discomfort for people wearing contact lenses.

Q: What is the risk of hair thinning or hair loss while using Alitretinoin?

Hair loss, or alopecia, is a known potential side effect of the oral capsules. Official product information classifies alopecia as a common side effect, meaning it is reported to affect between 1 and 10 in every 100 patients.

Q: Are there any known interactions between Alitretinoin and consuming alcoholic beverages?

The medicine is officially associated with very common increases in blood fat levels, specifically hypertriglyceridemia and hypercholesterolemia. Because excessive alcohol intake can also affect these blood fat levels, regulatory guidance suggests consulting a healthcare professional due to the combined effect on blood fat levels.

Q: Is Alitretinoin used to treat common skin conditions like typical acne or ordinary eczema?

No. Alitretinoin (oral capsules) is only officially indicated for the treatment of severe chronic hand eczema that is unresponsive to potent topical corticosteroids. It is not indicated for the treatment of common acne or ordinary eczema.

Q: Is Alitretinoin classified as a chemotherapy drug or a retinoid?

Alitretinoin is pharmacologically classified as a retinoid, which is a substance chemically derived from vitamin A. While the topical gel formulation is used to treat localized skin growths associated with AIDS-related Kaposi’s sarcoma, the drug's core class and mechanism remain retinoid.

Q: Does the skin condition treated by Alitretinoin usually look worse before it begins to improve?

For the topical gel formulation, official adverse event reporting indicates that local skin reactions typically begin as redness (erythema) and irritation. This can potentially worsen, sometimes resulting in swelling and peeling or shedding of the skin with continued use.

Q: Are there risks for the baby if a man who is taking Alitretinoin fathers a child?

Official safety data indicates that the amount of Alitretinoin transferred through the semen of male patients is not great enough to be associated with teratogenic effects in their female partners. This data informs the safety constraint that barrier contraception is not required for men regarding teratogenicity risk.

Q: How often is it necessary to have blood tests while taking Alitretinoin capsules?

Regular monitoring is required due to the potential for the medicine to affect blood fat and liver enzyme levels. Official guidelines state that these levels must typically be checked before starting treatment, again one month after the start of treatment, and then subsequently every three months.

Q: What does 'unresponsive to potent topical corticosteroids' mean in the official use criteria for Alitretinoin?

Official regulatory information indicates this phrase refers to severe chronic hand eczema that has not responded adequately, showed only a temporary response, or was not tolerated after at least eight weeks of treatment with potent topical corticosteroid therapy.

How should Alitretinoin be stored and disposed of?

Official Storage and Disposal Requirements

Alitretinoin storage conditions are based on the specific formulation to maintain product stability.

Requirement	Oral Capsules	Topical Gel
Temperature	Store at room temperature le 30 C (86 F)	Store at room temperature 20 C to 25 C (68 F)
Environment	Protect from excess heat, moisture, and light.	Protect from heat, moisture, and direct light.
Handling	Do not freeze and keep the container tightly closed.	Do not freeze; must be kept away from open flame as it is flammable.
Child Safety	Keep this and all medication out of the reach of children.	Keep this and all medication out of the reach of children.

Disposal Instructions: Unused or expired Alitretinoin should be discarded using a drug take-back program when available. If a program is not accessible, the medicine should be mixed with an undesirable substance (like coffee grounds), placed in a sealed bag, and thrown into the household trash. It must not be flushed down a toilet or poured down a drain unless explicitly instructed by the labeling.

Alitretinoin